NeuExcell’s technology has the potential to regenerate brain tissue in a damaged area caused by a wide variety of neurodegenerative conditions such as stroke, Huntington’s disease (HD), ALS, Alzheimer’s disease (AD), Parkinson’s disease (PD), spinal cord injury, Amyotrophic Lateral Sclerosis (ALS) and many other rare neuro-genetic conditions. We have generated a robust pre-clinical data package that supports the potential of the technology platform, with a focus on our two lead indications, ischemic cortical stroke and Huntington’s disease. IND enabling studies are ongoing for ischemic cortical stroke and Huntington's programs. We are aiming for IND filing for stroke program late 2021 and for HD program early 2022. Our current pipeline also includes AD and ALS programs which are both in late animal POC stage.